[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566655":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":37,"locations":45,"responsibleParty":79,"collaborators":81,"id":86,"slug":28,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":28,"enrollmentInfo":94,"targetDuration":28,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":68,"whyStopped":28,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Cyclosporine A (CsA) 0.1%","EXPERIMENTAL","After one week of hourly natamycin eye drops the participants in this arm will use this drop four times a day for one month then twice a day for one month.",[13],"Drug: Cyclosporine A",{"label":15,"type":10,"description":11,"interventionNames":16},"Cyclosporine A (CsA) 2%",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR",[21],"Other: Placebo Comparator: Placebo",[23,29],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cyclosporine A","Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.",[9,15],null,{"type":6,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"Placebo Comparator: Placebo",[18],[33],{"name":34,"affiliation":35,"role":36},"Gerami D Seitzman, MD","UCSF Proctor Foundation","PRINCIPAL_INVESTIGATOR",[38,42],{"name":34,"role":39,"phone":40,"phoneExt":28,"email":41},"CONTACT","4154761442","gerami.seitzman@ucsf.edu",{"name":43,"role":39,"phone":28,"phoneExt":28,"email":44},"Thomas Lietman, MD","tom.lietman@ucsf.edu",[46,66],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"University of California, San Farncisco","NOT_YET_RECRUITING","San Francisco","California","94143","United States",{"type":54,"coordinates":55},"Point",[56,57],-122.41942,37.77493,{"lat":57,"lon":56},[60,62],{"name":34,"role":39,"phone":61,"phoneExt":28,"email":41},"415-476-1442",{"name":63,"role":39,"phone":64,"phoneExt":28,"email":65},"Brianna K Colado, BA","5593492629","brianna.colado@ucsf.edu",{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"cosmosGeoPoint":28,"geoPoint":28,"contacts":73},"Aravind Eye Institute","RECRUITING","Pondicherry","Tamil Nadu","605 007","India",[74,77],{"name":75,"role":39,"phone":28,"phoneExt":28,"email":76},"Josephine Christy, MD","josephine@aravind.org",{"name":78,"role":39,"phone":28,"phoneExt":28,"email":28},"Kunal Mandlik, MD",{"type":80,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[82,84],{"name":83,"class":6},"Aravind Eye Hospitals, India",{"name":85,"class":6},"Aravind Eye Care System","100566655",false,"NCT06658002","Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","FANCY","Inclusion Criteria:\n\n* Inclusion is based on presenting acuity, not ulcer size.\n* Inclusion of 20\u002F40 = 6\u002F12 = 0.3 Log MAR and 20\u002F400 = 3\u002F60 = +1.3 Log MAR.\n* Smear or culture positive for fungal keratitis, any length.\n* Age 18 years.\n* Willing to participate in study.\n\nExclusion Criteria:\n\n* Co-infection with bacterial or viral keratitis.\n* Corneal perforation.\n* Requiring therapeutic keratoplasty for fungal keratitis.\n* Unwilling or unable to follow up (e.g., living too far from hospital).\n* Presenting acuity better than 20\u002F40 = 6\u002F12 = 0.3 Log MAR or worse than 20\u002F400 = 3\u002F60 = +1.3 Log MAR.\n* Subjects taking cyclosporine at any concentration on presentation.\n* Acuity worse than 20\u002F200 = 6\u002F60 = +1.0 Log MAR in unaffected eye.\n* Pregnant women.\n* Penetrating Keratoplasty.\n* Presents with a 0-7 day history of topical steroid.","ALL","18 Years",{"count":95,"type":96},150,"ESTIMATED","INTERVENTIONAL",[99],"PHASE3","The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.",[102,103],"Fungal Keratitis","Corneal Ulcer",[103,25,102,105],"Fungal Corneal Ulcer","2026-06-03",{"date":108,"type":109},"2026-06-05","ACTUAL",{"date":111,"type":109},"2025-09-01",{"date":113,"type":96},"2027-09-01",{"name":5,"class":6},2]